Cost effectiveness, big talent pool, and a large population in India has made the country attractive for the investors to look for conducting clinical trials, health care and life sciences areas, said Mukundan CV, general manager, life sciences division, SysArris Software Pvt. Ltd. Speaking to BioSpectrum, he said, "it will take time for a developing country like India to get more funds. This is mainly because the sector is still in a disorganized shape as against the chain of networks in the western world. From drug discovery to the end application, the drug takes a proper channel, that makes a lot of difference. However, the process of drug discovery, clinical trails and development of genomics, proteomics takes a long period and require huge investments. It is only because of these factors the investors are not coming forward for investments in India.

"But we cater to the entire drug discovery and development process from genomics, proteomics and screening to data management tools for pre and post clinical trials registration and post marketing adverse reaction tracking, " he added.